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Abstract: Trophic factors control cellular physiology by activating speciﬁ  c receptor tyrosine kinases (RTKs). While the 
over activation of RTK signaling pathways is associated with cell growth and cancer, recent ﬁ  ndings support the concept 
that impaired down-regulation or deactivation of RTKs may also be a mechanism involved in tumor formation. Under this 
perspective, the molecular determinants of RTK signaling inhibition may act as tumor-suppressor genes and have a poten-
tial role as tumor markers to monitor and predict disease progression. Here, we review the current understanding of the 
physiological mechanisms that attenuate RTK signaling and discuss evidence that implicates deregulation of these events 
in cancer.
Abbreviations: BDP1: Brain-derived phosphatase 1; Cbl: Casitas B-lineage lymphoma; CIN-85: Cbl-interacting protein 
of 85 kDa; DER: Drosophila EGFR; EGFR: Epidermal growth factor receptor; ERK 1/2: Extracellular signal-regulated 
kinase 1/2; Grb2: Growth factor receptor-bound protein 2; HER2: Human epidermal growth factor receptor 2; LRIG: 
Leucine-rich repeats and immunoglobulin-like domain 1; MAPK: Mitogen-activated protein kinase; Mig 6: Mitogen-induc-
ible gene 6; PTEN: Phosphatase and tensin homologue; RET: Rearranged in transformation; RTK: Receptor tyrosine kinase. 
SH2 domain: Src-homology 2 domain; SH3 domain: Src-homology 3 domain; Spry: Sprouty.
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Introduction
The signals that control cell fate determination and coordinate the development of the organs needs to 
be exquisitely regulated in both time and space. Activation of RTKs by their cognate trophic factors is 
among the signals that are critically involved in morphogenesis, inducing signaling pathways that control 
cellular processes such as cell proliferation, differentiation, migration and survival (Ullrich and Schlessinger, 
1990). Thus, to avoid signaling errors that ultimately lead to aberrant cellular behavior and disease, 
cellular mechanisms have evolved to ensure that appropriate signaling thresholds are achieved and 
maintained during the right period of time. 
RTKs are single spanning transmembrane proteins possessing an intrinsic kinase activity. Upon 
ligand binding, the kinase is activated and autophosphorylates itself on tyrosine residues located within 
the cytoplasmic tail, creating docking sites for proteins containing phosphotyrosine-binding domains 
and forming the starting-point for a variety of different signaling cascades that regulate cell physiology. 
In particular, Ras-Erk/MAP kinase and phosphatidylinositide-3 kinase (PI3K)-AKT pathways represent 
two critical signaling cascades induced upon the activation of RTKs by trophic factors (Blume-Jensen 
and Hunter, 2001).
The deregulation of approximately ﬁ  fty percent (30 of 58) of the genes known to encode RTKs are 
associated with human tumors (Blume-Jensen and Hunter, 2001). Several mechanisms that increase the 
catalytic activity of RTKs (positive signaling) have been identiﬁ  ed. Examples of these mechanisms 
include chromosomal translocation, receptor ampliﬁ  cation and point mutations (Blume-Jensen and 
Hunter, 2001; Lamorte and Park, 2001). Since over activation of RTK signaling has been implicated in 
the onset and progression of different human disorders and cancer, it is essential to understand how 
RTKs are down-regulated and deactivated. Unlike positive signals, which are relatively well understood, 
the molecular mediators of signal desensitization are currently under intensive study. During the last 
years, biochemical and genomic techniques as well as genetic analyses of developmental processes 
have led to the identiﬁ  cation and characterization of the mechanism of action of several RTK signaling 46
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inhibitors (Table 1). These studies have under-
scored the importance of negative-feedback control 
of RTK function as a mechanism to ensure 
signaling thresholds compatible with the induction 
of a physiological response (Casci and Freeman, 
1999; Fiorini et al. 2002; Ghiglione et al. 1999; 
Golembo et al. 1996; Tsang and Dawid, 2004). A 
common feature of these feedback loops is the 
transcriptional induction of negative attenuators 
by the same pathways that are eventually inhibited 
(late attenuators). Negative feedback is one of the 
mechanisms that provide an effective control of 
RTK signaling. However other mechanisms, 
collectively known as receptor down-regulation, 
have been evolved to restrict RTK signaling inde-
pendently of transcription (early attenuators) 
(Haglund et al. 2003b; Thien and Langdon, 2001). 
This type of molecular machinery exists prior to 
receptor activation thereby limiting signal propaga-
tion through promoting the receptor ubiquitination, 
endocytosis and degradation. 
RTKs coordinate a wide variety of biological 
processes and are therefore subjected to multiple 
levels of control. Multiple modes of action have 
been described to inhibit RTK signaling. In Figure 1, 
we illustrate this concept describing the mecha-
nisms through which different physiological 
inhibitors antagonize and restrict trophic factor 
signaling, including ligand sequestration and 
binding inhibition, attenuation of RTK autophos-
phorylation, induction of inhibitory proteins that 
counteracts downstream signaling pathways and 
ligand-induced receptor ubiquitination. Therefore, 
this review focuses on recent advances made in the 
understanding of the physiological mechanisms 
that restrict RTK signaling and summarizes their 
putative dysfunction in neurological diseases and 
cancer.
Mechanisms of RTK Signaling 
Attenuation 
Ligand sequestration and binding 
inhibition
In Drosophila, activation of epidermal growth 
factor receptor (EGFR) homologue, DER is strictly 
regulated. DER is a receptor tyrosine kinase 
required for developmental processes throughout 
life cycle (Perrimon and Perkins, 1997; Schweitzer 
and Shilo, 1997) and different mechanisms have 
been described for modulation of this signaling. 
The secreted protein Argos is the only known 
extracellular inhibitor of DER (Schweitzer et al. 
1995) with a clear physiological role during devel-
opment. Argos is a secreted protein of 444 aa with 
an atypical EGF-like motif (Freeman et al. 1992) 
identiﬁ  ed as an inhibitor of DER signaling by 
genetic deletions (Freeman et al. 1992; Golembo 
et al. 1996; Wasserman and Freeman, 1998). While 
Argos mutant embryos show hyperactivation of 
DER signaling (Golembo et al. 1996), the addition 
of Argos resulted in the abrogation of DER activa-
tion by its ligand, Spitz (Schweitzer et al. 1995), 
indicating a role to Argos as a negative regulator 
of DER. Although several reports have argued that 
Argos interacts directly with DER (Jin et al. 2000; 
Schweitzer et al. 1995; Vinos and Freeman, 2000), 
recently it has been shown that Argos inhibits DER 
signaling by sequestering its activating ligand 
(Klein et al. 2004). During the last years Kekkon1 
emerged as a new inhibitor of DER. In contrast to 
Argos, Kekkon1 is a single spanning transmem-
brane protein with leucine-rich repeats (LRR) and 
immunoglobulin (Ig) motifs (Musacchio and 
Perrimon, 1996). In developmental assays, it was 
demonstrated that loss of Kekkon1 activity results 
in increased DER signaling, whereas ectopic 
expression of the gene suppressed receptor activa-
tion, suggesting that Kekkon acts as a negative 
regulator of DER activity. In this case, the inhibi-
tion involves a physical interaction between both 
the extracellular and transmembrane domains of 
Kekkon1 with DER (Ghiglione et al. 1999). Thus, 
Kekkon1 inhibits ligand binding and autophos-
phorylation of the receptor, resulting in the 
suppression of downstream signaling events. Inter-
estingly, the expression of Argos as well as 
Kekkon1, are induced by DER activation (Ghiglione 
et al. 1999; Golembo et al. 1996; Schweitzer et al. 
1995) therefore representing a negative feedback 
mechanism.
Although we do not know yet whether a mamma-
lian Argos equivalent exists, the mammalian protein 
structurally related to Kekkon1, LRIG1 (leucine-
rich repeats and immunoglobulin-like domain 1) 
has been described. Interestingly, LRIG1 has been 
shown to inhibit mammalian EGFR activation by a 
different mechanism (see Table 1). 
Even though evidences for RTK regulation by 
ligand sequestration come from studies made in 
Drosophila, they suggest new possible strategies 
for the design of novel anti-oncogene agents. 
Future studies are required to develop new 47
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Table 1. Classiﬁ  cation of RTK signaling inhibitors according to their mechanisms of action.
Attenuator  Type of attenuator  Inhibitory target  Mechanism of action  References
Argos  Late/reversible  Drosophila   Ligand sequestration  Klein et al. 2004
   EGFR  (DER)
Kekkon  Late/reversible  DER  Inhibition of trophic  Ghiglione 
      factor binding  et al. 2003
E-Cadherin  Early/reversible  EGFR, IGFR and  Adhesion-dependent RTK   Qian et al. 2004
    Met receptor  inhibition. Decrease of 
     ligand  afﬁ  nity
BDP1  Early/reversible  ErbB2R  Reduction of ErbB2R   Gensler
phosphatase      autophosphorylation  et al. 2004
Herstatin  Early/reversible  ErbB2R  Reduction of ErbB2R  Doherty 
      dimerization and activation.  et al. 2001;
      Sequestration of  Hu et al. 2006
      ErbB2R in the ER.
Mig6/Ralt/  Late/reversible  EGFR, ErbB2 and  Inhibition of EGFR/ErbB2R  Hackel et al.
Gene33    Met receptors  autophosphorylation and  2001;
      Met-Rho-like GTPase   Pante et al. 2005
     pathway
PTP1B   Early/reversible  EGFR and IGFR  Reduction of EGFR and  Liu and Chernoff 
phosphatase     IGFR  autophosphorylation  1997;  Elchebly 
        et al. 1999
SAP (Slam-  Early/reversible  TrkA, TrkB and TrkC  Reduction of Trk receptor  Lo et al. 2005
associated       autophosphorylation
protein)
Decorin  Early/irreversible  EGFR and ErbBR   Inhibition of EGF-dependent  Iozzo et al. 1999;
    family members  EGFR dimerization and  Zhu et al. 2005
      induction of protracted 
     internalization  and 
      degradation of the EGFR
PTEN  Early/reversible  Several RTKs  Inhibition of PI3K-Akt   Stambolic et al.
      pathway  1998; Lu et al.
       1999
Sef  Late/reversible  FGFR  Inhibition of Ras-MAPK  Tsang et al. 2004;
      pathway  Torii et al. 2004
Sprouty  Late/reversible  Several RTKs  Inhibition of Ras-MAPK   Gross et al. 2001;
      pathway  Yusoff et al. 2002
Synaptojanin  Early/reversible  EGFR  Inhibition of PI3K-Akt   Woscholski et al.  
     pathway  1997
c-Cbl  Early/irreversible  Several RTKs  Receptor ubiquitination and  Thien and    
     degradation  Langdon  2005
LRIG1  Late/irreversible  EGFR/ErbB  Enhancement of receptor   Gur et al. 2004; 
    receptor family  ubiquitination and   Laederich et al. 
     degradation  2004
Nedd proteins  Early/irreversible  IGF1R, VEGFR  Induction of receptor   Murdaca et al.
    and TrkA  ubiquitination and down-  2004; Vecchione 
     regulation  et  al.  2003;
        Arevalo et al.
       2006
Nrdp1  Early/irreversible  ErbB2R, ErbB3R,   Ligand-independent ErbB  Qiu and Gold-
    ErbB4R   receptor degradation  berg 200248
Ledda and Paratcha
Biomarker Insights 2007: 2
Figure 1. Different mechanisms of RTK signal attenuation. (A) Ligand-sequestration and binding inhibition. This panel illustrates the inhibi-
tory role of the secreted protein Argos, which negatively regulates DER signaling sequestering the DER-activating ligand Spitz and prevent-
ing Spitz binding to DER. (B) Inhibition of RTK autophosphorylation. Examples of this type of inhibition include the cytosolic adapter/scaffold 
protein Mig6/Ralt/Gene33 and the PTP1B phosphatases. Mig6 binds to the intracellular domain of the EGFR and inhibits its autophos-
phorylation. Another way by which EGFRs can become deactivated is by the action of PTP1B protein tyrosine phosphatases that reduce 
ErbB2 receptor phosphorylation. (C) Inhibitory proteins that counteract downstream signaling. Trophic factor stimulation activates the Ras-
Erk1/2 pathway, which ends in the induction of the Sprouty gene. Then, Sprouty in a negative-feedback loop deactivates this cascade by 
inhibiting the pathway at undetermined intermediates. The role of the phosphatidylinositol phosphatase PTEN as a speciﬁ  c attenuator of the 
RTK-PI3K-Akt pathway is also indicated. (D) Ligand-induced receptor ubiquitination and degradation. This panel illustrates the mechanism 
of RTK down-regulation mediated by the ubiquitin ligase c-Cbl. Trophic factor binding to a RTK induces receptor autophosphorylation via 
receptor dimerization, followed by the subsequent activation of the Ras-Erk1/2 and PI3K-Akt signaling pathways. The ubiquitin-ligase c-Cbl 
interacts with the tyrosine-phosphorylated RTK and mediates its multi-ubiquitination. Receptor ubiquitination facilitates endocytosis and 
posterior lysosomal degradation of activated RTKs.
reagents that can neutralize RTK ligands, which 
overexpression is involved in the development of 
different malignancies.
During the last years, a new mechanism of RTK 
negative regulation was described (Andl and 
Rustgi, 2005). In contrast to ligand sequestration, 
this mechanism involves a decrease in the RTK 
ligand affinity, mediated i.e. by E-cadherin. 
Although E-cadherin was originally described as 
a structural cell surface glycoprotein involved in 
cell-cell adhesion, later it was shown to have 
signaling function. During the last years, E-
cadherin was found to interact through its extracel-
lular domain with EGFR, Hepatocyte growth factor 
receptor (HGFR/MET) and Insulin-like growth 
factor receptor (IGFR-1), thereby decreasing 
receptor mobility and its afﬁ  nity for their ligand. 
Interestingly, the interaction of E-cadherin with 
RTKs does not impair E-cadherin dimerization and 
adhesive function (Qian et al. 2004). Thus, the 
increased cell motility and invasiveness observed 
in E-cadherin negative tumors that has been usually 
attributed to the loss of cell adhesion, could also 
be explained in part by the loss of cell adhesion-
dependent RTK inhibition.
Inhibition of RTK autophosphorylation
Inhibition of RTK autophosphorylation can be 
achieved by protein tyrosine phosphatases (PTPs). 
Several studies have shown that PTPs speciﬁ  cally 
dephosphorylate certain subsets of phosphorylated 
tyrosines on RTKs that have multiple phosphory-49
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lation sites, indicating a certain degree of selec-
tivity (Kovalenko et al. 2000; Ostman et al. 2006; 
Persson et al. 2004). Several PTPs has been 
reported to be able to regulate RTK activity by 
abrogating receptor autophosphorylation and 
subsequently blocking downstream signaling. The 
inappropriate activity of PTPs leads to aberrant 
tyrosine phosphorylation that contributes to the 
development of cancer (Hunter, 2000). One 
example is the phosphatase PTP1B that impairs 
EGFR activation (Lammers et al. 1993). Fibro-
blasts from PTP1B-deﬁ  cient mice show an increase 
and sustained EGFR phosphorylation after growth 
factor treatment (Haj et al. 2003). Another example 
of RTK-regulating tyrosine phosphatase is the 
RPTPσ, whose activity has been implicated in the 
negative regulation of EGF receptor activation and 
downstream signaling (Suarez Pestana et al. 1999). 
Recently, the PEST-type protein-tyrosine phospha-
tase BDP1 emerged as a new regulator of ErbB2. 
While the overexpression of BDP1 inhibited 
ligand-induced activation of ErbB2, the suppres-
sion of endogenous BDP1 expression increased its 
phosphorylation. Moreover, BDP1 was able to 
interfere with downstream signaling events, 
reducing MAPK activation (Gensler et al. 2004). 
SHP-1 has also been identiﬁ  ed as a phosphoty-
rosine phosphathase that negatively regulates the 
nerve growth factor (NGF) receptor, TrkA. SHP-1 
interacts with TrkA at tyrosine 490 and controls 
both the basal NGF-stimulated level of TrkA 
activity in developing peripheral neurons (Marsh 
et al. 2003). Another potential negative regulator 
of Trk signaling is the SLAM-associated protein 
(SAP). SAP protein interacts with the TrkA, TrkB 
and TrkC neurotrophin factor receptors in vitro and 
in vivo. Binding of SAP requires Trk receptor 
activation and phosphorylation of the tyrosine 674, 
which is located in the activation loop of the kinase 
domain. Moreover, overexpression of SAP attenu-
ates tyrosine phosphorylation of Trk receptors 
and suppress NGF-induced neurite outgrowth 
(Lo et al. 2005).
 During the last years Mitogen-inducible gene 
6 (Mig6 also known as RALT or Gene 33) was 
identiﬁ  ed as a feedback inhibitor of different RTKs. 
Several studies indicate that Mig6 can attenuate 
mitogen signaling induced by EGF, Heregulin 
(HRG-β) and Hepatocyte growth factor (HGF/
MET) (Fiorentino et al. 2000; Fiorini et al. 2002; 
Hackel et al. 2001; Pante et al. 2005; Xu et al. 
2005). The molecular mechanisms underlying the 
inhibition achieved by Mig6 is still controversial. 
In the case of EGF and ErbB2 receptors, it was 
shown that Mig6 is able to suppress their signaling 
by directly binding to the RTKs and inhibiting the 
EGFR/ErB2 receptor autophosphorylation there-
fore attenuating the MAPK signaling (Anastasi 
et al. 2003). In line with these results, the deletion 
of the mouse gene encoding Mig6 shows hyperac-
tivation of endogenous epidermal growth factor 
receptor and sustained signaling through MAPK, 
resulting in the overproliferation and impaired 
differentiation of keratinocytes (Ferby et al. 2006). 
Moreover, these mice develop spontaneous tumors 
in different organs supporting a role for Mig6 as a 
novel tumor suppressor of EGFR-dependent malig-
nancies. On the other hand, Mig6 was found to 
inhibit the signaling triggered by HGF by indirectly 
binding to its tyrosine kinase receptor, MET, 
through the adaptor protein Grb2 (Pante et al. 
2005). Interestingly, it was shown that part of 
Mig6’s mechanism of action involves the inhibition 
of the GTPase Cdc42. The overexpression of Mig6 
was able to inhibit the HGF/MET-induced cell 
migration and neurite outgrowth (Pante et al. 
2005). However, the physiological relevance of 
MET attenuation in Mig6-deﬁ  cient mice has not 
been reported and deserves additional analysis.
Few natural ligands that inhibit RTK activation 
have been identiﬁ  ed to date. Herstatin protein 
belongs to this short list of natural ligands that 
attenuate RTKs. Herstatin is a secreted product of 
the ErbB2 gene containing a truncated extracellular 
domain. Herstatin has been shown to disrupt 
receptor dimerization and reduce ErbB2 receptor 
phosphorylation (Doherty et al. 1999) More 
recently, Hu et al. (2006) reported a novel and 
intracellular mechanism by which Herstatin could 
attenuate ErbB2 receptor activity. In this case, 
Herstatin has the ability to reduce ErbB2 receptor 
levels on the cell surface by sequestration of ErbB2 
receptors in the endoplasmic reticulum (ER). In 
this model, Herstatin decreases ErbB2 receptor 
translocation from ER to cell surface (Basson 
et al. 2005; Hu et al. 2006).
Inhibitory Proteins that Counteract 
Downstream Signaling
The majority of the biological processes induced 
upon RTK engagement require the precise stimula-
tion of Erk/MAP kinase family members and 
activation of PI3K and Akt kinases. Increasing 50
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interest in negative regulation of RTK signaling 
has led to the identiﬁ  cation of different pathway-
speciﬁ  c inhibitors. Although during the last years 
several negative regulators of RTK downstream 
signaling have been described, mounting evidence 
highlights the role of Sprouty, Sef and PTEN 
proteins as both selective and physiological inhib-
itors of Erk/MAPK and PI3K-Akt signaling path-
ways respectively.
The Sprouty (Spry) family of proteins has 
emerged as a major class of trophic factor-inducible 
antagonists of RTK signaling. In particular, 
Sprouty proteins appear to speciﬁ  cally inhibit the 
Ras-Raf-Erk1/2 pathway, leaving the PI3K and 
other MAPK pathways intact (Gross et al. 2001; 
Yusoff et al. 2002). The negatively regulated 
mammalian RTKs include Fibroblast growth factor 
receptor (FGFR), Hepatocyte growth factor 
receptor (HGFR/MET), Vascular endothelial 
growth factor receptor (VEGFR) and Glial cell-line 
derived neurotrophic factor (GDNF) receptor, RET 
(Impagnatiello et al. 2001; Kramer et al. 1999; 
Reich et al. 1999; Sasaki et al. 2003). The levels 
at which Sprouty proteins block Erk/MAPK activa-
tion are still unclear and the evidence to date 
suggest the existence of mechanisms that depend 
on the cellular context and the RTK considered.
More recent biochemical and genetic evidence 
indicate speciﬁ  c roles for the Sprouty genes during 
normal development and multiple modes of action 
of the Sprouty proteins in the regulation of RTK-
induced responses. As a negative regulator, Sprouty 
itself is subject to tight control at multiple levels. 
Speciﬁ  cally, growth factors increase the levels of 
the Sprouty transcripts, regulate the recruitment of 
Sprouty proteins to the plasma membrane and 
modulate Sprouty activity through rapid and tran-
sient tyrosine phosphorylation (Y55) (Mason et al. 
2004). In particular, phosphorylation of Sprouty 
proteins on a tyrosine residue located at position 
55 is required for its ability to inhibit RTK-induced 
Ras-Erk1/2 signaling (Mason et al. 2004; Sasaki 
et al. 2001) However, phosphorylation of this 
evolutionarily conserved tyrosine is also necessary 
for the interaction of Sprouty with c-Cbl, an E3 
Ubiquitin ligase that mediates the direct ubiquitina-
tion and degradation of several RTKs (Hall et al. 
2003; Mason et al. 2004; Rubin et al. 2003). There-
fore, Sprouty protein levels are controlled through 
a phosphorylation-dependent complex formed with 
c-Cbl. Polyubiquitination and degradation of an 
active Sprouty might limit its inhibitory effects to 
a deﬁ  ned period after receptor engagement. Intrigu-
ingly, several studies have also demonstrated that 
mammalian Sprouty proteins can increase EGF-
mediated Erk/MAPK signaling in a cell type-
dependent manner (Egan et al. 2002; Rubin et al. 
2003; Wong et al. 2002). This novel agonistic effect 
of Sprouty is strictly dependent on c-Cbl. In this 
particular case, Sprouty bound to c-Cbl, competes 
and prevents c-Cbl-mediated ubiquitination and 
down-regulation of activated EGF receptors 
(EGFRs), yielding sustained levels of activated 
EGFR and resulting in a net increase in down-
stream signaling. In summary, the c-Cbl-Sprouty 
interaction emerges as a critical signaling event 
important in controlling the antagonistic function 
of Sprouty and, at the same time, the life cycle of 
Sprouty proteins themselves.
Another molecule that belongs to this category 
of inhibitors is Sef (Similar expression to fgf 
genes). This newly identiﬁ  ed antagonist encodes 
a putative Type I transmembrane protein that is 
conserved across zebraﬁ  sh, mouse and human 
(Kovalenko et al. 2003). Sef protein restricts FGFR 
signaling by acting as a feedback-induced antago-
nist of the Ras/MAPK-mediated FGF signaling 
(Furthauer et al. 2002). Interestingly, mouse Sef 
(mSef) also attenuates FGF-induced activation of 
PKB (PKB/AKT), a key protein in the PI3K 
pathway (Kovalenko et al. 2003). Neverthless, the 
precise mechanism of the inhibitory effect of Sef 
remains controversial, since it has also been 
reported that Sef may antagonize FGF signaling 
by binding to and restricting FGFR tyrosine phos-
phorylation (Kovalenko et al. 2003). In addition, 
it has been reported that alternative splicing of the 
human Sef (hSef) gene alter the subcellular local-
ization of this protein and diversify the repertoire 
of RTKs to be inhibited (Preger et al. 2004).
Finally, PTEN (also referred to as MMAC1 and 
TEP1) is another attenuator that has been impli-
cated in negative signaling by RTKs. This phos-
phatidylinositol phosphatase is implicated in 
negative signaling that speciﬁ  cally inhibits PI3K-
Akt signaling pathway triggered by RTKs. This 
pathway is a key regulator of cell proliferation, 
motility and survival. The activity of Akt is regu-
lated by PI3K via the synthesis of phosphatidyl 
inositol 3, 4, 5-triphosphate (PIP3). PTEN antago-
nizes PI3K by degrading PIP3 to phosphatidyl 
inositol 4, 5-biphosphate (PIP2). Deregulation of 
Akt through loss of functional PTEN has been 
implicated in the progression of different tumors 51
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(Simpson and Parsons, 2001). In agreement with 
this, the down-regulation of PTEN results in an 
increased concentration of PIP3 and Akt hyperac-
tivation leading to protection from apoptotic 
stimuli (Stambolic et al. 1998). In contrast, over-
expression of PTEN in cancer cell lines results in 
the inactivation of Akt and cell cycle arrest (Lu 
et al. 1999).
Ligand-induced Receptor Ubiquitina-
tion and Degradation (Receptor 
Down-regulation)
Down-regulation of RTKs is an irreversible mech-
anism of inhibition that regulates the extent of the 
signal by removing activated receptors from the 
plasma membrane. Once activated, RTKs are 
ubiquitinated, internalized and targeted for degra-
dation to the lysosomal compartment or locally 
destroyed in proteasomes. Many of these processes 
are regulated by ubiquitination, a post-traslational 
modiﬁ  cation where the small protein ubiquitin is 
covalently attached to a target protein. While poly-
ubiquitination marks proteins for proteasomal 
degradation, mono- or multi-ubiquitination is 
sufﬁ  cient to direct endocytosis and lysosomal 
degradation of membrane receptors (Haglund 
et al. 2003a; Haglund et al. 2003b; Thien and 
Langdon, 2001). 
Central to the process of receptor down-regula-
tion are the roles of Cbl and Nedd families of 
ubiquitin-protein ligases, which act through 
limiting signal propagation independently of new 
transcriptional events (Harvey and Kumar, 1999; 
Thien and Langdon, 2005). Recently, Arevalo 
et al. (2006) have identiﬁ  ed the E3 Ubiquitin ligase 
Nedd4-2 as an enzyme that binds speciﬁ  cally to 
the c-terminal portion of the TrkA receptor 
(Arevalo et al. 2006). The binding of Nedd4-2 to 
activated TrkA leads to the ubiquitination and 
down-regulation of TrkA and to the modulation of 
neuronal survival by NGF. In contrast, several 
other activated receptors, such as EGFR (ErbB1), 
Platelet-derived growth factor receptor (PDGFR), 
RET and MET receptors are ubiquitinated upon 
interaction with c-Cbl, the most studied member 
of the Cbl family. By virtue of their tyrosine kinase-
binding (TKB) domain, c-Cbl can directly asso-
ciate with activated receptors by the binding of its 
SH2 domain to speciﬁ  c tyrosine residues on the 
receptor. However, Cbl also interacts with the SH3 
domain of Grb2, an adaptor protein known to 
associate with phosphorylated receptors and link 
RTK to the activation of the Ras pathway. Thus, 
in mammalian cells Grb2 can indirectly recruit 
c-Cbl to EGFR, MET and RET receptors (Jiang 
et al. 2003; Scott et al. 2005).
Consistent with its role in the down-regulation 
of RTKs, dominant negative mutants of c-Cbl 
lacking ubiquitin ligase activity have been identi-
ﬁ  ed in mouse tumors (Thien and Langdon, 2001). 
In addition to the targeting of RTKs for lysosomal 
degradation after ubiquitination, several evidences 
support a role for c-Cbl in the endocytosis of RTKs. 
In particular, the overexpression of c-Cbl increases 
the rate of EGFR internalization (Soubeyran et al. 
2002). It has been shown that c-Cbl promotes the 
internalization of RTKs by binding to the CIN-
85-Endophilin complex, a step required for the 
invagination of the plasma membrane into the 
coated-pits (Petrelli et al. 2002; Soubeyran et al. 
2002). Inhibition of Cbl-CIN85-Endophilin inter-
action was sufﬁ  cient to block RTK endocytosis 
and degradation, without disrupting the ability of 
Cbl to ubiquitinate activated receptors (Petrelli 
et al. 2002; Soubeyran et al. 2002).
Recent studies have also linked RTK ubiquitina-
tion to receptor endocytosis (Marmor and Yarden, 
2004; Mosesson et al. 2003). A number of endo-
cytic regulatory proteins have been demonstrated 
to interact with ubiquitin and coordinate the traf-
ﬁ  cking of ubiquitinated RTKs from endosomes to 
lysosomes. Examples include Hrs, Eps15, Stam, 
Epsin and Tsg101 proteins. Interestingly, the 
kinetic properties and the magnitude of the 
signaling response of the RTK may be regulated 
by the location of the activated receptor along the 
endocytic pathway (Burke et al. 2001). Since RTKs 
can transmit signals from the membrane of the 
endosomes, the molecular machinery that control 
the trafﬁ  cking of receptors from early endosomes 
to degradative lysosomes represent key proteins in 
the down-regulation of receptor signals. Therefore, 
any alterations that uncouple RTKs from ligase-
mediated ubiquitination, internalization and down-
regulation are tightly associated with cancer. 
Recent studies have identiﬁ  ed the mammalian 
leucine-rich repeats and immunoglobulin-like 
domain 1 (LRIG1) protein as an endogenous inter-
actor of c-Cbl (Gur et al. 2004; Laederich et al. 
2004). LRIG1 is a transmembrane protein with an 
ectodomain containing 15 leucine-rich repeats 
(LRRs) and three immunoglobulin-like motifs. The 
structural similarity of LRIG1 with other inhibitors 52
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previously described in insects (Kekkon) led to the 
prediction that LRIG1 could interact and restrict 
EGF signaling in mammalian cells. Notably, disrup-
tion of the Lrig1 gene in mice resulted in fertile 
animals that develop skin defects, suggesting 
involvement in EGFR signaling regulation (Suzuki 
et al. 2002). Based on these two evidences, it has 
been reported that LRIG1 is a negative feedback 
regulator of the four EGFR mammal orthologs 
(ErbB1, ErbB2, ErbB3 and ErbB4). The underlying 
mechanism involves the upregulation of LRIG1 and 
a subsequent direct EGFR-LRIG1 interaction 
followed by an enhanced recruitment of c-Cbl 
leading to accelerated ubiquitination and degradation 
of EGFRs (Gur et al. 2004; Laederich et al. 2004).
Based on the premise that the LRR domain is 
the critical interacting domain between LRIG1 and 
the EGF/ErbB receptor family, Goldoni et al. 
(2006) demonstrated that a soluble ectodomain of 
LRIG1, containing only the LRRs, repress both 
ligand-independent and ligand-dependent EGFR 
activation and ERK1/2 signaling in a dose-dependent 
manner (Goldoni et al. 2006). In contrast to the 
entire protein, this attenuation occurs without any 
signiﬁ  cant internalization and degradation of the 
receptor. Thus, inhibition of EGFR activity without 
down-regulation of the receptor could represent a 
novel therapeutic approach toward malignancies 
in which EGFR has a primary role promoting 
tumor growth.
Finally, Decorin represents another example of 
the negative regulation of EGF/ErbB receptors by 
proteins containing leucine-rich repeats. Decorin 
is a secreted proteoglycan molecule that acts as an 
inhibitor of mammalian EGFRs (Iozzo et al. 1999). 
In particular, Decorin leads to the protracted inter-
nalization and degradation of the EGFR (Zhu 
et al. 2005). Additional inhibition of EGF-mediated 
EGFR dimerization and activation by soluble 
Decorin has been reported. Interestingly, this novel 
and dual mechanism of action could explain the 
anti-oncogenic properties of Decorin.
Repressors of RTK Signaling as 
Tumor-suppressor Genes
Over activation of RTK signaling is a common 
feature of cellular transformation and malignancy. 
Based in this concept, several groups began inves-
tigating the role of negative regulators of trophic 
factor-mediated signaling in cancer. They 
described that the expression of speciﬁ  c RTK 
attenuators is down-regulated in different types 
of human cancer. These studies led to the identi-
fication of specific tumor-suppressor genes, 
whose dysfunction or their down-regulation 
results in promoting malignancy. In this section, 
we highlight recent progresses in understanding 
the defective attenuation of RTK signaling in 
cancer and discuss their potential for the develop-
ment of effective therapeutic approaches. In 
particular, we provide evidences for a role of the 
protein attenuators: PTEN, Mig6, LRIG1 and 
Sprouty in human cancer.
PTEN
The tumor suppressor PTEN is localized at chro-
mosome 10q23, which has been observed to be 
mutated in different sporadic cancers. Loss of 
chromosome 10q is the most common genetic 
alteration that is associated with the most aggres-
sive form of glioma, glioblastoma multiforme 
(GBM) (Fults and Pedone, 1993; von Deimling 
et al. 1993). Several reports have indicated a high 
frequency of PTEN mutations in glioblastomas 
(Chiariello et al. 1998; Duerr et al. 1998; Liu and 
Chernoff, 1997; Teng et al. 1997; Wang et al. 
1997). Studies at the level of PTEN expression 
in glioblastomas versus lower grade gliomas 
suggest that the reduction of PTEN is important 
in the progression from gliomas to GBM stage 
(Sano et al. 1999). Another tumor type that 
frequently exhibits loss of chromosome 10q is 
prostate carcinoma. PTEN mutations have been 
described in this carcinoma and it has been 
suggested that the inactivation of PTEN occurs 
mainly in advanced prostate cancer. In agreement 
with this, PTEN immunohistochemical analysis 
has correlated its decreased expression with 
pathological markers of poor prognosis (McMe-
namin et al. 1999). Thus, down-regulation of 
PTEN expression may play a role in the develop-
ment of advanced prostate cancer. Interestingly, 
homozygous inactivation of Pten is embryonic 
lethal in mice. However, Pten 
+/– mice show 
hyperplastic-dysplastic features and are highly 
susceptible to develop epithelial tumors (Di Cris-
tofano et al. 1998; Di Cristofano et al. 2001; 
Podsypanina et al. 1999; Suzuki et al. 1998). 
Recently, it has been described that conditional 
prostate-speciﬁ  c deletion of the murine Pten gene 
leads to metastatic prostate cancer (Wang et al. 
2003). In melanoma, PTEN mutations also appear 53
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to be associated with late stages of the disease 
(Reifenberger et al. 2000; Tsao et al. 2000; Zhou 
et al. 2000). Different studies reported that the 
frequency of PTEN mutations is higher in patients 
with metastatic melanoma compared with primary 
tumors (Reifenberger et al. 2000; Tsao et al. 
2000). Several studies examining endometrial 
carcinomas indicate a high frequency (approxi-
mately 50%) of PTEN mutations (Risinger et al. 
1997; Tashiro et al. 1997). Interestingly, only a 
small fraction of breast cancer cases, show 
mutations in PTEN (Bose et al. 1998; Feilotter et 
al. 1999; Rhei et al. 1997; Ueda et al. 1998). 
It is known that the recombinant anti-ErbB2 
monoclonal antibody, Herceptin, has remarkable 
therapeutic efficacy in patients with ErbB2-
overexpressing tumors. The mechanism underlying 
Herceptin’s antitumor activity includes the down-
regulation of p185
ErbB2 receptor and the subsequent 
inhibition of its downstream PI3K-Akt signaling 
pathway (Hudziak et al. 1989; Yakes et al. 2002). 
Despite this, the causes of Herceptin resistance are 
not well understood. Recently, it has been reported 
that loss of PTEN in breast cancer cells overex-
pressing ErbB2 confers resistance to Herceptin 
treatment (Nagata et al. 2004). In particular, 
patients with PTEN-deﬁ  cient breast cancers have 
signiﬁ  cantly poorer responses to Herceptin-based 
therapy than those with normal PTEN, suggesting 
that PI3K-targeting therapies could overcome this 
resistance.
Mig6
Mig6 chromosomal locus is located within the 
region 1p36.1–3, which has been described to be 
mutated in different human cancers (Koshikawa 
et al. 2004; Ogunbiyi et al. 1997; Tseng et al. 2005). 
During the last years it has been reported that Mig6 
expression is down-regulated in patients with 
breast cancer and short survival time (Amatschek 
et al. 2004). More recently, it was shown that Mig6 
expression is reduced in skin, breast, pancreatic 
and ovarian carcinomas (Ferby et al. 2006). Inter-
estingly the loss of Mig6 in mice results in the 
hyperactivation of endogenous EGFR signaling, a 
high incidence of neoplastic lesions, and high 
susceptibility to carcinogen-induced formation of 
papillomas and melanomas (Ferby et al. 2006). 
These ﬁ  ndings suggest that loss of Mig6 may be 
used as a novel marker in the process toward 
malignancy.
LRIG1
LRIG1 is located at chromosome 3p14.3, which 
has been reported to be mutated in different tumor 
types. Its expression is down-regulated in tumor 
cell lines derived from lung, prostate and colon 
when compared to normal tissue (Hedman et al. 
2002). Loss of heterozygosity at the LRIG1 locus 
was found in human breast cancers (Maitra et al. 
2001). Another malignancy where LRIG1 expres-
sion was found to be down-regulated is renal cell 
carcinoma (Thomasson et al. 2003). Moreover, in 
squamous cell carcinoma, low levels of LRIG1 
expression has been correlated with increased 
metastasis and poor patient survival, (Tanemura 
et al. 2005) suggesting that the down-regulation of 
LRIG1 provides a novel prognostic predictor in 
this malignancy.
Sprouty
Down-regulation of Spry1 and Spry2 has been 
described in breast cancer. Using cDNA arrays 
containing pairs of cDNAs generated from tumor 
and normal tissue samples from individual 
patients, a high frequency in the down-regulation 
of Spry1 (78%) and Spry2 (96%) have been 
observed. These ﬁ  ndings were conﬁ  rmed by real 
time PCR (Lo et al. 2004). Different studies indi-
cate that Sprys are also down-regulated in prostate 
cancer. Using tissue microarrays containing pairs 
of samples from tumors and normal peripheral 
tissue, Spry1 was shown to be decreased in 39% 
of prostate cancer compared with matched normal 
prostate tissue (Kwabi-Addo et al. 2004). 
However, a considerable fraction of the tumors 
exhibited a higher expression of Spry1 to the 
corresponding peripheral tissue indicating that, 
although decreased Spry1 expression is seen in a 
substantial fraction of prostate cancers, loss of 
Spry1 expression is not required in all prostate 
cancers. In a more recent study, it was reported 
that Spry2 expression is reduced in high-grade 
clinical prostate cancer when compared to benign 
prostatic hyperplasia (McKie et al. 2005). Studies 
in renal cell carcinomas indicate that Spry1 is 
upregulated in patients with a good outcome. 
More recently it was described that the expression 
of Spry2, but not Spry1, is down-regulated in liver 
cancer (Fong et al. 2006). The mechanisms by 
which Spry is down-regulated in the different 
cancer types remain unclear but might be speciﬁ  c 
to different malignancies. Although in the cases 54
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presented above, Spry expression seems to be a 
marker for good clinical prognosis, in other cancer 
types Sprouty expression is controversial. Tsava-
chidou et al. (2004) has described an upregulation 
of Spry2 in melanoma cells with B-Raf V599E 
mutations compared to melanocytes with wild type 
B-Raf (Bloethner et al. 2005; Tsavachidou et al. 
2004). Therefore, future studies are needed to 
deﬁ  ne whether Spry has a tumor suppressor role.
Conclusions and Perspectives
Recent advances in the understanding of the 
mechanisms involved in down-regulating RTKs 
and restricting their signaling has been summarized 
above. The overall picture that emerges from these 
studies indicates that the mechanisms of regulation 
occur at numerous levels, including ligand binding, 
receptor autophosphorylation, induction of inhib-
itory proteins that counteract downstream signaling 
pathways and receptor endocytosis and degrada-
tion. Another important concept is related to the 
fact that negative feedback loop is one of the 
mechanisms that has evolved to provide an effec-
tive way of controlling RTK-mediated signaling.
Conclusions derived from the work outlined in 
this review indicate that RTK activity is tightly 
controlled through the coordinated action of 
several negative protein regulators that function at 
multiple levels of the signaling cascade, and at 
different time-points after receptor engagement. 
Recent evidence also demonstrates that certain 
inhibitors have multiple mechanisms of action that 
depend on the cellular context and the identity of 
the RTK inhibited.
In addition to protein attenuators, microRNAs 
(miRNAs) have emerged as an abundant class of 
small (approx. 22-nucleotides) non-protein-coding 
RNAs that play an important role in the negative 
regulation of gene expression, controlling the 
translational efﬁ  ciency of target mRNAs (Esquela-
Kerscher and Slack, 2006). MicroRNAs have been 
shown to regulate a wide range of developmental 
processes modulated by RTKs, like proliferation, 
survival and differentiation. Recently, several 
miRNAs have been associated with human cancer. 
Interestingly, miRNAs can function as tumor-
suppressor and oncogenes (Lee and Dutta, 2006; 
Mendell, 2005) and might become a powerful tool 
to aid in the diagnosis and treatment of cancer. 
Despite the advances in the identification of 
speciﬁ  c miRNAs, our understanding of their target 
mRNAs in normal and pathological conditions is 
at very preliminary stage. Therefore, future studies 
will help to elucidate whether miRNAs could 
represent a new and alternative mechanism to 
down-regulate RTK signaling during normal devel-
opment and disease.
Many important aspects of RTK signaling inhi-
bition still remain unanswered. One signiﬁ  cant 
issue that requires a more detailed investigation is 
the exact identiﬁ  cation of the signaling pathways 
regulated by these inhibitory molecules and, 
particularly, their in vivo function.
The elucidation of the mechanisms that control 
RTK activation is today seen as one of the major 
challenges in biomedical science. Neurotrophic 
factor signaling through their RTK receptors play 
critical roles in the development of the nervous 
system, in the survival and maintenance of speciﬁ  c 
subpopulations of differentiated neurons. While the 
over activation of RTK signaling due to impaired 
deactivation of RTK signaling is associated with 
cancer, it is also possible that alterations in these 
control mechanisms could contribute to the patho-
genesis of neurodevelopmental diseases and neuro-
degenerative disorders. In particular, individuals 
with germline PTEN mutations display brain disor-
ders including macrocephaly, seizures and mental 
retardation (Waite and Eng, 2002). Interestingly, 
PTEN mutations has been reported in individuals 
with autism spectrum disorders (ASD) (Butler et al. 
2005; Gofﬁ  n et al. 2001; Zori et al. 1998). A recent 
study showed that deletions of Pten in the mouse 
central nervous system can underlie macrocephaly 
and behavioral abnormalities reminiscent of certain 
features of human ASD (Kwon et al. 2006). There-
fore, another general issue consists in identify and 
describe the expression of these attenuators in tissue 
isolated from different neurological pathologies.
Finally, a more complete understanding of these 
emergent mechanisms will have wide implications 
in medicine, particularly in the identiﬁ  cation of 
tumor-suppressor markers and in the design of efﬁ  -
cient therapeutic approaches to human diseases.
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